The challenges facing the life science industry have never been greater. Healthcare payers are demanding greater value for their money, at a time when pharmaceutical companies are facing a period of diminishing expectations due to loss of patent protection for many blockbuster drugs and poor pipeline productivity. To meet these challenges, the life science industry is undergoing a transformation, exploring new markets, sourcing more R&D externally, and entering into collaborations with academic, government, and other stakeholders, all of which has led to a fragmentation of the value chain. To support these structural changes within the industry, drive innovation, and optimize efficiency, life science companies are increasingly turning to advances in technology. The expectation is that new technologies will cut cycle times to market, implement new commercial models, facilitate collaboration with diverse partners, and further the promise of personalized medicine.
- Strategy, selection, and deployment of IT products and solutions in the life sciences in North America, Europe, and Asia-Pacific regions
- Analysis of enterprise technologies such BI and analytics, CRM, ERP, and SCM
- Analysis of pharma-specific technologies such as lab informatics, e-clinical IT, drug safety solutions, detailing solutions
- Analysis of regulatory compliance programs such as EHR and track and trace
- The impact of trends such as cloud and Big Data on the healthcare ecosystem
- The contribution of new technologies to drug discovery programs and the advent of personalized medicine
2013 Signature Research
- Dealing with the health sciences data deluge
- Personalized medicine is the ultimate goal
- Cloud computing is not just for data
- Big pharma is turning to emerging markets for growth
- May 17 - 17:25 | Nvidia’s CUDA-on-ARM work holds promise for HPC | http://t.co/aTkQbhkz4Q #finance
- May 17 - 15:49 | @sunrisesoftware Thanks!
- May 17 - 15:45 | @kim_crosby We're glad you enjoyed it! Thanks for the shout out :)